Repare Therapeutics Completes Acquisition by XenoTherapeutics; Shares to Delist from Nasdaq

summarizeSummary

This 8-K filing confirms the consummation of the previously announced acquisition of Repare Therapeutics by XenoTherapeutics, Inc. The completion of this transaction fundamentally alters the investment thesis for Repare Therapeutics, as it ceases to be an independent publicly traded company. Shareholders will receive a cash payment of approximately $2.20 per share, plus one non-transferable contingent value right (CVR) for each share, offering potential future payments. The company's shares will be delisted from Nasdaq, and it will cease to be a reporting issuer, marking the end of its public trading life. This follows the shareholder approval of the acquisition on January 16, 2026.

check_boxKey Events

• Acquisition Consummated

  Repare Therapeutics Inc. has completed its acquisition by XenoTherapeutics, Inc. and Xeno Acquisition Corp. on January 28, 2026, as previously approved by shareholders.

• Shareholder Consideration

  Shareholders received a cash payment of approximately US$2.20 per common share, plus one non-transferable contingent value right (CVR) for each share, representing potential future payments.

• Delisting and Deregistration

  The company has notified Nasdaq to suspend trading of its shares effective after January 28, 2026, and will proceed with delisting from Nasdaq and deregistration under the Exchange Act.

• Board and Management Changes

  All directors of Repare Therapeutics resigned, and the sole director and officer of the acquirer, Jon Adkins, became the sole director and officer of the surviving corporation.

auto_awesomeAnalysis

This 8-K filing confirms the consummation of the previously announced acquisition of Repare Therapeutics by XenoTherapeutics, Inc. The completion of this transaction fundamentally alters the investment thesis for Repare Therapeutics, as it ceases to be an independent publicly traded company. Shareholders will receive a cash payment of approximately $2.20 per share, plus one non-transferable contingent value right (CVR) for each share, offering potential future payments. The company's shares will be delisted from Nasdaq, and it will cease to be a reporting issuer, marking the end of its public trading life. This follows the shareholder approval of the acquisition on January 16, 2026.